Vanda Pharmaceuticals (VNDA) Total Liabilities (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Total Liabilities data on file, last reported at $152.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 26.75% year-over-year to $152.8 million; the trailing twelve-month figure through Mar 2026 stood at $152.8 million (up 26.75% YoY), and the FY2025 full-year result was $161.8 million, up 37.48% from the prior year.
• Total Liabilities slipped to $152.8 million in Q1 2026, from $161.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $161.8 million in Q4 2025 to a low of $98.5 million in Q3 2023.
• A 5-year average of $116.2 million and a median of $108.7 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities retreated 7.19% in 2023 and surged 37.48% in 2025, its largest moves.
• Tracing VNDA's Total Liabilities over 5 years: stood at $107.0 million in 2022, then dropped by 3.29% to $103.5 million in 2023, then gained by 13.65% to $117.7 million in 2024, then soared by 37.48% to $161.8 million in 2025, then fell by 5.56% to $152.8 million in 2026.
• Business Quant data shows VNDA's Total Liabilities at $152.8 million in Q1 2026, $161.8 million in Q4 2025, and $135.1 million in Q3 2025.